Thirty

Thirty Madison identified a critical gap in how Americans managed chronic conditions like migraine and erectile dysfunction. Patients faced months-long waits to see specialists, then paid exorbitant out-of-pocket costs for treatments. The problem hit hardest among middle-income Americans who couldn't afford concierge care but earned too much for safety-net programs. The inefficiency was measurable: specialty care visits cost $200-400, with patients waiting 60+ days for appointments. Existing alternatives—traditional dermatology and urology practices—operated on high-overhead models that made serving this population unprofitable. Telemedicine startups existed but lacked clinical depth for chronic disease management. Early validation came through direct patient demand: when Thirty launched its migraine program, they achieved 40% month-over-month growth without paid acquisition, indicating genuine market pull. Repeat prescription rates above 60% proved patients found real value, not just convenience. This organic traction demonstrated the company had solved a problem people would actively pay for.

Thirty Madison charged patients a flat monthly subscription ($30-$50) for chronic condition management, bundling telehealth consultations with medications. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Before scaling, co-founder Steve Gutentag validated willingness-to-pay through direct patient conversations and small pilot programs, testing whether people would actually commit to recurring payments for convenience and affordability compared to traditional healthcare. The revenue model relied on subscription retention rather than transaction volume, making unit economics critical from day one. Early validation came when patients consistently renewed subscriptions month-over-month, demonstrating genuine value beyond initial interest. Insurance reimbursement partnerships provided additional revenue streams, reducing customer acquisition costs. The key signal validating their approach was achieving positive unit economics quickly—customers paid reliably, and the operational costs of serving them decreased with scale. This early proof that the model worked financially, not just theoretically, allowed Gutentag to build an operationally-intensive business without falling into the trap of unsustainable unit economics that plague many healthcare startups.